Keyword: American Society of Hematology
At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.
A phase 1/2b test showed Roche's antibody mosunetuzumab can trigger durable responses in a significant minority of hard-to-treat NHL patients.
Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.
In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.
Scientists running the first trial of CRISPR-edited cells to fight cancer are reporting that the therapy has been well tolerated by three patients.
The week’s news included antibodies that lower the risks of bone marrow transplants and a new way to target a mutation in epilepsy.
Bluebird Bio has been singing the praises of two new therapies at ASH, but investors don’t seem to be fully on board with the program.
At ASH, Fate will present preclinical data on three off-the-shelf, cancer-fighting cell therapies made from stem cells.
Bluebird Bio and Celgene built on impressive early responses in multiple myeloma, with their CAR-T therapy extending PFS to 11.8 months in phase 1.
At the annual ASH meeting, oncologists at the Dana-Farber Cancer Institute demonstrated how simple blood tests may hold promise for managing multiple myeloma.